Evidence map›Paper›PMID 38496468›Full record

ArticlebioRxiv : the preprint server for biology2024

Immune Signatures of SARS-CoV-2 Infection Resolution in Human Lung Tissues.

Devin Kenney, Aoife K O'Connell, Anna E Tseng, Jacquelyn Turcinovic, Maegan L Sheehan, Adam D Nitido, Paige Montanaro, Hans P Gertje, Maria Ericsson, John H Connor and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Devin KenneyDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Aoife K O'ConnellDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Anna E TsengDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Jacquelyn TurcinovicDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Maegan L SheehanRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Adam D NitidoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Paige MontanaroNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Hans P GertjeNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Maria EricssonElectron Microscopy Core Facility, Harvard Medical School, Boston, MA, USA.
John H ConnorDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8867-7256
Vladimir VrbanacRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Nicholas A CrosslandDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-3873-9188
Christelle HarlyUniversité de Nantes, INSERM, CNRS, CRCINA, Nantes, France.ORCID 0000-0002-8045-9166
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-1767-3944
Florian DouamDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-4791-6767
Boston University · USRagon Institute of MGH, MIT and Harvard · USCentre National de la Recherche Scientifique · FRHarvard University · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
RESEARCH TRAINING IN IMMUNOLOGYT32AI007309 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 1988 to 2024
$7.4M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Eliminating the Immunogenicity of AAV Vectored HIV Antibody DeliveryR01AI174276 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Alejandro Benjamin Balazs · 2024 to 2026
$2.5M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
Vectra Polaris Quantitative Pathology Imaging SystemS10OD030269 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2021 to 2021
$402k
Characterization of a human-specific positive regulator of flavivirus infectionK22AI144050 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DOUAM, FLORIAN · 2021 to 2023
$344k
Ventana Discovery Ultra Research Autostainer: an Ex+ Core serviceS10OD026983 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2019 to 2019
$207k
NCATS NIH HHS UL1 TR001430NIAID NIH HHS K22 AI144050NIAID NIH HHS R01 AI174276NIAID NIH HHS R01 AI174875NIAID NIH HHS T32 AI007309NIDA NIH HHS DP2 DA040254NIH HHS S10 OD026983NIH HHS S10 OD030269
6 · The paper itself

Abstract

While human autopsy samples have provided insights into pulmonary immune mechanisms associated with severe viral respiratory diseases, the mechanisms that contribute to a clinically favorable resolution of viral respiratory infections remain unclear due to the lack of proper experimental systems. Using mice co-engrafted with a genetically matched human immune system and fetal lung xenograft (fLX), we mapped the immunological events defining successful resolution of SARS-CoV-2 infection in human lung tissues. Viral infection is rapidly cleared from fLX following a peak of viral replication, histopathological manifestations of lung disease and loss of AT2 program, as reported in human COVID-19 patients. Infection resolution is associated with the activation of a limited number of hematopoietic subsets, including inflammatory monocytes and non-canonical double-negative T-cells with cytotoxic functions, which are highly enriched in viral RNA and dissipate upon infection resolution. Activation of specific human fibroblast and endothelial subsets also elicit robust antiviral and monocyte chemotaxis signatures, respectively. Notably, systemic depletion of human CD4+ cells, but not CD3+ cells, abrogates infection resolution in fLX and induces persistent infection, supporting evidence that peripheral CD4+ monocytes are important contributors to SARS-CoV-2 infection resolution in lung tissues. Collectively, our findings unravel a comprehensive picture of the immunological events defining effective resolution of SARS-CoV-2 infection in human lung tissues, revealing markedly divergent immunological trajectories between resolving and fatal COVID-19 cases.

Identifiers

PMID38496468
PMCPMC10942442
OpenAlexW4392624449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.